ClinicalTrials.Veeva

Menu
N

NRC Research Institute | Orange, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KarXT
Rapastinel
BHV-7000
Troriluzole
SHP465
MK-8189
BI 425809
Iclepertin
RVT-3101
ML-004

Parent organization

This site is a part of NRC Research Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 79 total trials
Locations recently updated

A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia

This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called...

Enrolling
Schizophrenia
Device: Digital therapeutic (CT-155)

X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of...

Enrolling
Major Depressive Disorder
Drug: Placebo
Drug: Azetukalner

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of MK-2214 in adults with mild cognitive...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Biological: MK-2214

The primary purpose of this trial is to evaluate the safety and tolerability of centanafadine QD XR in pediatric subjects with ADHD.

Active, not recruiting
Attention Deficit/Hyperactivity Disorder
Drug: Centanafadine Hydrochloride

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules

X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult p...

Invitation-only
Major Depressive Disorder
Drug: Azetukalner

Bipolar disorder (BPD) is a chronic debilitating illness characterized by drastic swings in mood, energy and functional ability that affects the adul...

Active, not recruiting
Bipolar 1 Disorder
Drug: Endoxifen enteric-coated tablet (8 mg)
Drug: Placebo Tablets

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Enrolling
Major Depressive Disorder
Drug: BHV-7000
Drug: Placebo

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Invitation-only
Major Depressive Disorder
Drug: BHV-7000

ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and ad...

Enrolling
Autism Spectrum Disorder
Drug: ML-004 Placebo
Drug: ML-004 (IR)/(ER) tablet

ML-004-003 is a multi-center, open-label extension study that will enroll approximately 120 adolescent and adult subjects with ASD that have complete...

Invitation-only
Autism Spectrum Disorder
Drug: ML-004 (IR)/(ER) tablet

This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of RO7790121 (RV...

Active, not recruiting
Crohns Disease
Drug: RO7790121

This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of RVT-3101 in a...

Active, not recruiting
Crohn Disease
Drug: RVT-3101

This study is designed to assess the safety, tolerability, and pharmacokinetics (PK) of multiple doses and ratios of xanomeline and trospium chloride...

Enrolling
Psychiatric Disorders
Drug: KarX-EC
Drug: KarXT

The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive d...

Active, not recruiting
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

Trial sponsors

Boehringer Ingelheim logo
Karuna Therapeutics logo
Otsuka logo
Roche logo
Allergan logo
Biohaven logo
Biohaven logo
Pfizer logo
Janssen (J&J Innovative Medicine) logo
Merck Sharp & Dohme (MSD) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems